Phylogeny of the cestode family Escherbothriidae (Cestoda: Rhinebothriidea) reveals unexpected patterns of association with skate hosts.

The rhinebothriidean tapeworm family Escherbothriidae has recently been expanded to include the genus Ivanovcestus , species of which parasitise arhynchobatid skates. Similarities in morphology and host associations between Ivanovcestus and Semiorbiseptum - a genus yet to be assigned to one of the families in the order Rhinebothriidea - led us to explore the possibility that Semiorbiseptum might also belong in the Escherbothriidae. Morphological similarities with Scalithrium ivanovae , Scalithrium kirchneri and Rhinebothrium scobinae , all of which also parasitise arhynchobatid skates, raised questions regarding the generic placements of these species. In addition, new collections from the skate Sympterygia brevicaudata revealed two new species that morphologically resemble species of Ivanovcestus . A combination of morphological and molecular data were used to assess the generic placement of the newly discovered species and refine our understanding of the membership of the family Escherbothriidae. Sequence data for the D1-D3 region of the 28S rDNA gene were generated de novo for 14 specimens of 7 rhinebothriidean species and combined with comparable published data to represent all 6 families in the Rhinebothriidea in the analysis. The phylogenetic tree resulting from maximum likelihood analysis strongly supports the inclusion of the genus Semiorbiseptum in the family Escherbothriidae. Our work also suggests that the skate-hosted species previously assigned to Scalithrium and Rhinebothrium are also members of Semiorbiseptum and that Ivanovcestus is a junior synonym of Semiorbiseptum . Six species are transferred to Semiorbiseptum , bringing the total number of species in the genus to ten. The diagnosis of Semiorbiseptum is amended to accommodate the additional species. A second species in the previously monotypic type genus of the family, Escherbothrium , is described. The diagnosis of the Escherbothriidae is amended to include the new and transferred species. This study underscores the importance of integrating morphological and molecular data in bringing resolution to cestode systematics. We believe our findings provide a robust foundation for future research into the evolutionary history and host associations of cestodes within the order Rhinebothriidea and beyond. These also highlight the importance of expanding our understanding of skate-hosted cestodes. ZooBank: urn:lsid:zoobank.org:pub:8052AFCA-5FBD-4430-95F4-0E5E368DEA3D.

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients.

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

Quality assessment of randomised controlled trials in oral and maxillofacial surgery.

Randomised controlled trials are the best way to study the evaluation of treatments. We have evaluated the quantity and quality of clinical trials in three of the main journals in the specialty of oral and maxillofacial surgery between January 2010 and December 2016, using a scientometric analysis, and evaluation by the Jadad scale. In this period, 303 randomised controlled trials (5% of the total) were identified; the largest number of studies were from Asia (45%) followed by Europe (32%). The subgroup that concerned most studies was oral surgery. The mean score on the Jadad scale was 3.06 points, which means that 32% of the total studies had a low risk of bias. Studies that declared funding and adherence to Consolidated Standards of Reporting Trials (CONSORT) were given significantly higher scores (p<0.001) than studies that did not. We conclude that randomised controlled trials in oral maxillofacial surgery have evolved in both quality and quantity since previous surveys were published. The quality of trials was related to the presence of funding and adherence to CONSORT.